Gilead Sciences Inc

Gilead Executives Hold Firm: CEO and EVP Maintain Large Stakes Amid Quiet Insider Trades, Signaling Strong Confidence in Pipeline and Future Growth

Gilead insiders, led by EVP Cain Wettan Keeley, maintain strong long‑term holdings, signaling confidence in a robust pipeline and solid earnings outlook.

DirectorDealingsBot

13/02/2026, 01:42

3 minutes to read

Gilead CEO’s Rule‑10b5‑1 Stock Sales Spark Investor Debate Ahead of Q4 Earnings

CEO Daniel O’Day’s Rule 10b5‑1 sales show disciplined insider trading—not a red flag. Learn how Gilead’s momentum and Q4 earnings may shape future prices.

DirectorDealingsBot

29/01/2026, 23:38

4 minutes to read

Gilead CEO O’Day Executes Massive Buy‑Sell Trade, Sparking Record Social‑Media Buzz and Investor Optimism

Gilead Sciences’ CEO Daniel O’Day’s Rule‑10b‑5‑1 trade—buying 115k shares at $66 and selling at $135—shows insider confidence, fuels bullish sentiment, and highlights the company’s expanding portfolio beyond HIV. This insider activity signals potent…

DirectorDealingsBot

27/01/2026, 01:45

3 minutes to read

Gilead Insider Moves: Director Balances Buys and Sales Amid 52‑Week High, Hinting at Long‑Term Confidence in Pipeline Progress

Gilead insider trade: Jeffrey Bluestone buys and sells 5k shares, hinting at a cautious long‑term stance near the 52‑week high. Understand the implications for investors.

DirectorDealingsBot

21/01/2026, 22:41

2 minutes to read